[Cerebral amyloid angiopathy and atrial fibrillation: anticoagulant dilemma]

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Context:

• Cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF) are common in elderly patients.
• This combination presents a therapeutic challenge regarding anticoagulation.
• Patients face risks of both cardioembolic events from AF and cerebral hemorrhage from CAA.

Purpose:

• To address the lack of therapeutic consensus for anticoagulation in patients with both CAA and AF.
• To outline a risk-benefit assessment framework for long-term anticoagulation.
• To guide clinical decision-making in this complex patient population.

Summary:

• A multidisciplinary approach is crucial, evaluating four key risks: intracerebral hemorrhage (ICH) without anticoagulation, ischemic stroke risk without anticoagulation, increased ICH risk with anticoagulation, and reduced ischemic stroke risk with anticoagulation.
• Certain CAA phenotypes, like transient neurological episodes or superficial siderosis, indicate a higher ICH risk.
• Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (VKAs) due to a lower ICH risk. Regular clinical and radiological monitoring (every 6-12 months) is advised if anticoagulation is initiated.
• Left atrial appendage occlusion is an alternative if anticoagulation is contraindicated. Strict blood pressure control is vital for all patients to mitigate ICH risk.

Impact:

• Provides a structured approach to a complex clinical dilemma, potentially improving patient safety.
• Highlights the preference for DOACs and the importance of individualized risk assessment.
• Emphasizes the role of multidisciplinary teams and ongoing monitoring in managing anticoagulation for patients with comorbid CAA and AF.